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Background: The prevalence of depression in people with multiple sclerosis (PwMS) is high; however, symptoms
common to both conditions makes measurement difficult. There is no high quality overview of validation studies to
guide the choice of depression inventory for this population.
Methods: A systematic review of studies validating the use of generic depression inventories in people with MS
was conducted using MEDLINE and PsycINFO. Studies validating the use of depression inventories in PwMS and
published in English were included; validation studies of tests for cognitive function and general mental health
were excluded. Eligible studies were then quality assessed using the COSMIN checklist and findings synthesised
narratively by instrument and validity domain.
Results: Twenty-one studies (N = 5,991 PwMS) evaluating 12 instruments were included in the review. Risk of bias
varied greatly between instrument and validity domain.
Conclusions: The review of validation studies was constrained by poor quality reporting and outcome reporting
bias. Well-conducted evaluations of some instruments are unavailable for some validity domains. This systematic
review provides an evidence base for trade-offs in the selection of an instrument for assessing self-reported
symptoms of depression in research or clinical practice involving people with MS. We make detailed and specific
recommendations for where further research is needed.
Trial Registration: PROSPERO CRD42014010597
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Multiple sclerosis (MS) is a chronic condition affecting
the central nervous system. It is characterised by neuro-
logical symptoms and deficits that lead to increased dis-
ability and physical decline over 30–40 years [1].
Symptoms include fatigue, weakness, pain, cognitive im-
pairment, loss of vision, tremors, poor balance, and blad-
der, bowel, and sexual dysfunction [2]. The prevalence of
depression, which is strongly linked with a reduced qual-
ity of life, is high amongst people with MS (PwMS) with
around half having major depression at some point in* Correspondence: d.kaklamanou@gmail.com
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However, there is significant overlap in the somatic
symptoms common to depression and MS, principally fa-
tigue, pain, poor sleep and concentration, leading to con-
cerns over the measurement of depression in PwMS [5].
For instance, the Diagnostic and Statistical Manual [6] cri-
teria for depression includes common symptoms of MS
such as fatigue, poor concentration and sleep difficulties.
Other self-report measures of depressive symptoms in-
clude questions about health and work difficulties, which
are also common to MS [7]. As such, levels of depression
in MS may easily be overestimated, particularly when
using self-report measures. The debate over how to as-
sesses depression in the presence of a physical conditionle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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considerable debate as to whether depression inventories
which include somatic symptoms should be used, modi-
fied or abandoned in populations with chronic physical
conditions [9–12]. Despite the number of depression in-
ventories used to assess people with MS and studies valid-
ating their use, there remains an evidence deficit in this
area with only one pre-existing systematic review of such
measures [13]. Minden and colleagues [13] reviewed mea-
sures used to assess and manage a wide range of psychi-
atric disorders in PwMS of which depression was just one,
and sought to answer a number of clinical questions. The
review had broad scope, did not assess the methodological
quality of selected studies, and missed a large number of
validation studies associated with the use of generic de-
pression inventories in people with MS. Research studies
can provide biased results if they lack methodological
rigour [14]. To assess the report of research study accur-
ately, readers need transparent information on its methods
and results. This can be hampered if report authors fail to
provide complete and clear descriptions of key study in-
formation [15]. For this reason, the COSMIN group have
developed a critical appraisal checklist, which provides
standards for the evaluation of the methodological quality
of instrument validation studies [16]. The purpose of the
present study was to review the evidence for the validity
and reliability of self-report depression inventories in
PwMS, in line with the COSMIN standards, with the aim
of providing clinicians and researchers with a rational
basis for choice.
Methods
Protocol and registration
A protocol for this systematic review is available on the
PROSPERO database [17].
Eligibility criteria
Eligible studies recruited people with MS, with no restric-
tions on duration or course of disease. Studies with com-
parison groups, for instance people with other physical or
psychological conditions, were also included in the review.
We included any study evaluating the validity or reliability
of self-report instruments designed to assess depression.
Studies simply assessing levels of depression, rather than
the validity or reliability of measures, were not included.
Studies focusing on the validation or reliability of neuro-
psychological tests of cognitive function or assessing gen-
eral mental health or health-related quality of life, as
opposed to depression, were excluded. We included peer
reviewed research journal articles with primary research
data. Commentaries, letters, dissertations and editorial pa-
pers were excluded. There was no restriction placed on
publication date. Due to time and resource constraints,
only English language papers were included.Information sources
We searched electronic bibliographic databases for pub-
lished work as well as the reference lists of primary studies
included in the review and of relevant, previously published
reviews. We searched MEDLINE (from 1946 to 21.07.2014)
and PsycINFO (from 1806 to July Week 3 2014) through
OVID. Reference lists of eligible studies were checked and
further relevant citations, not picked up through the
searches of bibliographic databases, were included, along
with serendipitous finds. No contact was made with study
authors to retrieve unpublished information.
Search
The search strategy included synonyms for the following
terms: multiple sclerosis, depression assessment, validity
and reliability. MeSH terms, exploding terms and other
search devices relevant to each database were used to cre-
ate a more efficient search. The full electronic search
strategy for both databases is available on the PROSPERO
database [17].
Study selection
Two researchers (DK and either RW or DB) independently
screened titles and abstracts for eligibility; differences were
resolved by discussion with DH (5 papers [18–22]). The
full papers of eligible titles and abstracts were retrieved and
further reviewed for eligibility in the same way.
Data collection process and data items
A standardised data extraction form was used, which in-
cluded details about the study (authors, year, country), the
samples (size, diagnoses, method of recruitment, baseline
demographic characteristics), and types of validity or reli-
ability assessed, as defined by the COnsensus-based Stan-
dards for the selection of health status Measurement
INstruments checklist (COSMIN) checklist (e.g. internal
consistency, reliability, measurement error, criterion valid-
ity, structural validity, content validity, cross-cultural val-
idity) [23]. Outcome data were extracted as reported. One
member of the review team (RW) extracted data, a second
(DK) independently checked the extraction and a third
(DH) checked a proportion of the extraction from the two
members. When working through the COSMIN checklist,
any discrepancies between the data extracted from the pa-
pers and the definition of the checklist were discussed
within the team. For example, in one of the papers the
authours [24] did not report that they were investigating
construct validity, but reported the values for discriminant
and convergent validity. Within the COSMIN checklist,
construct validity includes aspects of structural validity,
hypothesis testing and cross-cultural validity. In that par-
ticular case we reported the discriminant and convergent
validity according to the COSMIN checklist and therefore
were reported under 'Hypotheses Testing'.
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With a number of studies using different cut points in the
evaluation of continuous variables we considered meta-
analysis inappropriate [25]. As no statistical synthesis was
planned, quality assessment was conducted for the pur-
poses of describing the conduct of the included studies.
DK assessed the included studies, unblinded, for generic
dimensions of methodological quality defined by the
COSMIN [23]. DH checked a 20 % random sample of rat-
ings, which included all the poor rated papers and a ran-
dom sample of the remaining papers and disagreements
were resolved by discussion.
Summary measures
We extracted the summary statistics, where reported, for
domains, measurement properties, and their different as-
pects (see COSMIN taxonomy for further detail [16]).
For the reliability (extended definition) domain, we ex-
tracted: (1) inter-item correlations for the measurement
property of internal consistency; item-subscale correla-
tions, item-total correlations and Cronbach’s alpha (to
assess internal consistency for the correlation between
items) [26], with alpha scores of 0.70 and above accept-
able by convention [27]; (2) Intraclass correlation coeffi-
cients (ICC) (with scores of 0.4–0.75 indicating fair to
good reliability and higher scores excellent) [28] or Pear-
son or Spearman correlation coefficients (with scores of
>0.7 considered acceptable [27]) for the measurement
property of test-retest reliability; (3) standard error of
measure (or statistics from which it could be derived)
for the measurement property of measurement error.
For the validity domain, we extracted three categories of
data. First, p values from F- or t-tests (with values less than
0.05 considered statistically significant), Cohen’s kappa (with
values of >0.6 considered good agreement) [29], Spearman’s
correlations (with scores of >0.7 considered acceptable [27])
and qualitative information on content validity. Second, nar-
rative reports of factor analysis and uni-dimensionality of
the items and, for confirmatory factor analysis (CFA), com-
parative fit index (CFI) and Tucker-Lewis Index (TLI) values
ranging from 0 to 1, with a value ≥ 0.9 generally considered
to indicate acceptable model fit, and the root mean square
error of approximation (RMSEA) values of < .08 considered
to indicate poor fit [30] (structural validity aspect), Pearson’s
correlations and narrative information about convergent val-
idity (hypotheses testing aspect), confirmatory factor analysis
and narrative information on translation (cross-cultural val-
idity aspect) for the measurement property of con-
struct validity. Third, we extracted correlations (r statistics
and p values), percentages, area under the curve (AUC),
positive and negative predictive values (PPVs and NPVs)
for continuous scores, or sensitivity and specificity at spe-
cified cut-points for dichotomous scores, for the measure-
ment property of criterion validity.Results
Study selection
Following the PRISMA reporting guidelines, the database
searches retrieved 465 records of which 433 related to Eng-
lish language articles (Appendix 1). Five additional records
were found through other sources; another review [13] and
through the reference list of included papers [20–22, 31, 32].
After the elimination of duplicates there were 389 unique
citations to screen of which 267 were excluded at the title
stage and a further 82 at the abstract stage. Forty full text
articles were retrieved for detailed assessment of eligibility,
of these; a further 19 were excluded (see Appendix 2 for
detailed reasons). Twenty-one studies (N = 5,991 people
with MS) were included in the review (Appendix 3).
Study characteristics
Included studies were published between 1995 and 2014
by teams based in the USA (n = 11 [7, 24, 33–41]),
Canada (n = 6 [42–47]), the UK [31], France [48], Italy
[49], and Estonia [50]. Only one study [49] examined the
cross culture validity of the questionnaire in Italy. The
median number of people with MS in the studies was
148 (Range = 42–1,717).
The median of the mean ages of people with MS re-
ported in 18 out of 21 studies (Appendix 3, data missing
from three studies [34, 42, 45]) was 45.79 years (range:
34.40–52.90). The median percentage of women reported
in 19/21 MS cohorts (data missing from two studies [35,
42]) was 73.90 % (range: 63.00–83.30 %). The median of
the mean of MS diagnosis in years reported in 11 out of
21 studies was 11.08 years (range: 6.6 - 19).
The included studies evaluated the reliability and/or
validity of: the Beck Depression Inventory (BDI; n = 4 [7,
24, 39, 47]) or BDI-II (n = 1 [24]) or short-form variants
the Fast Screen (BDI-FS) (n = 1 [36]) and ‘modified’
(mBDI) (n = 1 [41]); Center for Epidemiologic Studies
Depression Scale (CES-D; n = 4 [43–45, 48]); Chicago
Multiscale Depression Inventory (CMDI/MDI; n = 4 [35,
37, 40, 49]); Hospital Anxiety and Depression Scale
(HADS; n = 2 [31, 42]); Patient Health Questionnaire
(PHQ-9; n = 2 [33, 46]); CESD-10 (n = 1 [33]); Patient
Reported Outcome Measurement Information System
Depression 8-item bank (PROMIS-D-8; n = 1 [33]); Yale
Single Question (YSQ; n = 1 [34]); a two-item measure
of depression (‘During the past two weeks, have you
often been bothered by feeling down, depressed, or
hopeless?’ and ‘During the past two weeks, have you
often been bothered by little interest or pleasure in
doing things?’) (n = 1 [38]); and a one-item single
question (‘Are you depressed?’) (n = 1 [50]). For the
purposes of reporting we treat the BDI and BDI-II as
one, but short-form versions (BDI-FS, mBDI) as sep-
arate entities. All the measures identified in this re-
view are free to use with the exception of the BDI
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use (Table 1).
The included studies evaluated: construct validity
(n = 16 [7, 24, 31, 35–41, 43, 44, 46–49]); criterion validity
(n = 9 [31, 34, 36, 38, 42, 43, 47, 49, 50]); internal reliability
(n = 5 [24, 37, 46, 48, 49]); content validity (n = 4 [37, 46,
48, 49]); test-retest reliability (n = 2 [45, 49]); discriminant/
convergent validity [33]; evaluation of dimensionality [33];
and inter-item reliability [33] (Table 2).
The median sensitivity score of the measures used, re-
ported in six criterion validity studies (Table 4), was 73.15 %
(range: 25.00–90.00 %) [31, 34, 38, 42, 47, 50]. The median
specificity score of the measures used, reported in six stud-
ies, was 87.30 % (range: 46.00–98.00 %) [31, 34, 38, 42, 47,
50]. The median PPV score of the measures used, reported
in seven studies, was 90.00 % (range: 54.00–96.80 %) [34, 38,
42, 43, 47, 49, 50]. The median NPV score of the measures
used, reported in three studies, was 84.00 % (range: 78.50–
85.00 %) [34, 38, 47] (Tables 3 and 4).
Risk of bias within studies (COSMIN)
For the BDI / BDI-II and brief versions (BDI-FS, mBDI; see
Table 5), the quality of information was rated: fair for over-
all reliability (n = 2 [24, 39]); fair (n = 2 [36, 47]) or excellent
(n = 4 [7, 24, 39, 41]) for content validity; fair for hypothesis
testing (n = 7 [7, 24, 36, 39–41, 47]); fair for criterion val-
idity (n = 2 [36, 47]); fair for responsiveness (n = 1
[39]). No papers measured the structural validity or
cross-cultural validity of the BDI. For the BDI-FS and
the mBDI, no papers assessed reliability, structural
validity, cross-cultural validity, or responsiveness; and,
for the mBDI no paper assessed criterion validity.
For the CES-D, the quality of information was rated:
poor (n = 1 [33]) or fair (n = 1 [45]) for overall reliability;
fair (n = 1 [33]) or excellent (n = 2 [44, 48]) for content
validity; fair (n = 1 [33]) to good (n = 1 [48]) for struc-
tural validity; fair (n = 3 [33, 43, 44]) to good (n = 2 [45,
48]) for hypothesis testing; poor (n = 1 [43]) to fair (n = 1
[33]) for criterion validity; fair for responsiveness (n = 1
[45]). No paper assessed cross-cultural validity.
For the CMDI, the quality of information was rated: fair
for overall reliability (n = 2 [37, 49]); excellent for content
validity (n = 3 [35, 37, 49]); fair for structural validity (n =
1 [37]); fair for hypothesis testing (n = 3 [35, 37, 49]); poor
for cross-cultural validity (n = 1 [49]); fair for responsive-
ness (n = 1 [35]). No paper assessed criterion validity.
For the PHQ-9, the quality of information was rated:
poor for overall reliability (n = 2 [33, 46]); fair for content
validity (n = 2 [33, 46]); fair for structural validity (n = 1
[33]); fair for hypothesis testing (n = 2 [33, 46]); fair for cri-
terion validity (n = 1 [33]). No paper assessed cross-
cultural validity or responsiveness.
For the two-item measure, the quality for the informa-
tion was rated: excellent for content validity; fair forhypothesis testing and fair for criterion validity [38]; no
paper assessed overall reliability, structural and cross-
cultural validity or responsiveness.
For the HADS, the quality of information was rated: fair
(n = 1 [42]) to good (n = 1 [31]) for hypothesis testing; and,
fair (n = 1 [42]) to good (n = 1 [31]) for criterion validity.
For the YSQ, the quality for the information was rated: fair
(n = 1 [34]) for hypothesis testing; and, fair (n = 1 [34]) for
criterion validity. For the one-item measure, the quality
for the information was rated: fair (n = 1 [50]) for hypoth-
esis testing; and, fair (n = 1 [50]) for criterion validity. No
paper assessed reliability, content validity, structural valid-
ity, cross-cultural validity or responsiveness of the HADS,
the YSQ or the one-item measure.
Synthesis of results
BDI
For the reliability of the BDI (n = 2), internal consistency
was generally good (α = 0.86 for the full BDI-II [24]) with
a standard error of measurement (SEM) of 3.26 for test-
retest reliability [39], but only acceptable for the somatic
symptom cluster (α = 0.64 [24]). In studies of content
validity, people with MS and major depressive disorder
(MDD) had higher scores than controls (on the BDI-II
[24]) and were responsive to treatment [39]; one study
reported that the BDI lacked face validity for people with
MS [7], but this was contradicted by later studies [24,
39]. Studies tested hypotheses related to somatic symp-
toms common to MS and depression (n = 3 [7, 24, 39])
and the general utility of the instrument in people with
MS (n = 1 [47]). The findings for the studies were con-
flicted with one study providing evidence that the BDI
was sensitive enough to show difference in treatment
scores [39] and with other studies providing evidence
that the BDI is confounded by MS-related symptoms
[7]. All researchers called for more research on the over-
lap of MS and depression symptoms and the utility of
depression measures for PwMS. For criterion validity
(Table 4), using DSM-diagnosed MDD as a gold stand-
ard, the BDI demonstrated 71 sensitivity and 79 % speci-
ficity for a cut point of 13 points (mild depression [47]).
In studies of content validity, non-depressed PwMS
scored highly on a number of symptoms of depression
measured by the mBDI (Table 2 [41]), and face validity
was investigated for both the mBDI [41] and the BDI-FS
[36]. The BDI-FS was found to be more sensitive to
treatment effects than the HDRS (or HADS), whereas
Strober and Arnett [41], suggested a sort of hierarchy in
assessing depression in PwMS. Strober and Arnett [41]
suggested that the following (‘branch’) symptoms sad-
ness, pessimism, sense of failure, disappointment and
changes in appetite and/or weight were indicative of de-
pression in MS. On the other hand they suggested that
the following (‘trunk’) symptoms, fatigue, work difficulty,
Table 1 Reliability (Internal Consistency, Reliability & Measurement Error) Findings Based on Each Measure
Authors (Date) Measure Reliability (Cronbach’s Alpha) Internal consistency (Inter-Item Correlations) Test-test Reliability Measurement error
Moran & Mohr (2005) [39] BDI BDI SEM = 3.26;
HRSD SEM = 3.20
Aikens et al. (1999) [24] BDI-II Full BDI α = .86,
Cognitive / Affective α = .85
Somatic α = .64
BDI-18 α = .84
Amtmann et al. (2014) [33] PHQ-9; CESD-10;
PROMIS-D-8
PHQ-9 = .35-.67; CESD-10 = .33-.67;
PROMIS-D-8 = .75-.84
Sjonnesen et al. (2012) [46] PHQ-9 α = .82 Item-total correlations (PwMS):
anhedonia (.71); depressed mood (.65);
fatigue (.57) and concentration (.55).
Chang et al. (2003) [37] CMDI Sleep Disturbance α = .64
Cognitive Inefficiency α = .86
Fatigue α = .94
Evaluative α = .82
Mood α = .95
Solari et al. (2003) [49] CMDI MSVegetative α = .88
Evaluative α = .7
Mood α = .93
Item-subscale: mood = .58-.80,
evaluative = .37-.70, vegetative = .32-.57
ICC = 0.78 (95 % CI 0.62–0.89);
Subscales range 0.71–0.79 (2 weeks)
Patten et al. (2010) [45] CES-D r = .69 over 1 year; r = .70 over 2 years;
r = .65 over 3 years; r = .73 year 1-year 2;
r = .73 year 2-year 3
Verdier-Taillefer et al. (2001) [48] CES-D α = .90
Note: HRSD = Hamilton Rating Scale for Depression
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Table 2 Structural and Content Validity Findings by Measure
Authors (Date) Measure Structural Validity (Factor Analysis) Content Validity Item Inclusion
Mohr et al. (1997) [70]a BDI Fatigue, work difficulty, and concerns about
health (ps < .001) within MS population
Moran & Mohr (2005) [39] BDI All items showed significant reductions
following treatment (p < .05)
Aikens et al. (1999) [24] BDI-II MS had higher scores than healthy controls
on work difficulty, F = 8.05, p < .001 and sexual
disinterest, F = 9.99, p < .005.
Strober & Arnett (2010) [41] mBDI MS-NON-DEP: fatigue, indecision, loss of
libido, work difficulty, irritability, loss of
interest, crying, dissatisfaction, self-criticism.
DEP-PwMS: Irritability, loss of interest, crying,
dissatisfaction, self-criticism, sadness, pessimism,
failure, guilt, appetite, disappointment, weight
loss. MS (more severe in DEP-MS) or related to
depressive symptoms: irritability, loss of interest,
crying, dissatisfaction, self-criticism.
Amtmann et al. (2014) [33] PHQ-9; CESD-10;
PROMIS-D-8
Fit indices from a one-factor CFA were
acceptable. CFI for all models≥ of 0.95.
TLIs for PHQ-9 and CESD-10 < 0.95
(0.94 and 0.93, respectively). TLI > 0.95
for PROMIS-D-8. RMSEAs > .05 for any
of the measures.
Sjonnesen et al. (2012) [46] PHQ-9 Exclusion of fatigue and concentration items
no change in prevalence estimates (p > .05).
Fatigue item contributed the most to the
total score in both groups (MS 35.1 %
(95%CI 30.9–39.3), control 34.8 %
(95%CI 33.5–36.1). Item contribution
for fatigue and concentration items between
groups (p > .05). Anhedonia was lower in MS
than controls (OR 0.47, p = .03), PwMS positively
endorsed guilt (OR 2.17, p = .03) and fatigue
(OR 1.51, p = .05); frequency of endorsement
between groups (p > .05)
Patten et al. (2005) [44] CES-D Agreement between full and modified scales,
r = .99, 1.00, .98; k = .93, .96, .90. Prevalence for full
scale (>15) was 32.8 % (95%CI 18.9–36.8), exc.
fatigue 30.0 % (95%CI 26.3–34.0), exc. cognitive
31.0 % (95%CI 27.3–35.0), exc. both 30.4 %
(95%CI 26.6–24.4).
Verdier-Taillefer et al. (2001) [48] CES-D Factor 1 = depressed affect;
Factor 4 = interpersonal relationships.
Factor 2 = positive affect items
(MS group), but contained somatic
complaints (other groups);
Factor 3 = somatic complaints
(MS group) but positive affect
(other groups)
Chang et al. (2003) [37] CMDI CFA confirmed the subscale/factor
structure
Vegetative subscale showed misfitting in PwMS.
‘Fatigue’ and ‘useless’ items were endorsed more
by MS than controls.
Mohr et al. (2007) [38] Two-item measure The sensitivity and NPV of using either question
alone significantly better than either question
alone; the sensitivity of both questions was
significantly lower than other methods
Note: Studies that are not included in the table either did not assess content validity or did not report it. a ANOVAS but does not report f values. DEP = Depressed
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ing, dissatisfaction, self-criticism, were common in MS
but were indicative of depression if the symptoms were
disproportionate to the medical illness [41]. Thehypotheses tested related to the general validity of the
BDI-FS [36] and somatic symptoms common to MS and
depression for the mBDI [41]. The BDI-FS demonstrated
moderate correlations (internal consistency) with the
Table 3 Hypotheses Testing Findings by Measure
Authors (Date) Measure Discriminant Convergent
Aikens et al. (1999) [24] BDI-II BDI totals differed by group, F = 30.99, p < .001;
controls less depressed than MS, p < .05, and MS
less depressed than chronic pain patients, F = 12.9
p < .001. On the somatic subscale, MS scored higher
than all other groups (ps < .001), except diabetes
patients (ns)
BDI totals similar for MS and diabetes
F = 3.84, p = ns
Moran and Mohr (2005) [39] BDI BDI total score reduced from 23.7 (SD = 6.9) to 10.5
(SD = 6.5) following treatment, t = 10.91, p < .001
Sullivan et al. (1995) [47] BDI Participants with major depression scored significantly
higher on negative attitude towards self and performance
components, F(2,41) = 3.98, p < .05, F(2,41) = 3.42, p < .05,
but not on the somatic component, F(2,41) = 1.30, p = ns.
Benedict et al. (2003) [36] BDI-FS Groups differed in scores between treated and untreated
groups (anti-depressants), F = 13.26, p < .01, persisting
after controlling for physical disability. Treatment effect
size was largest for BDI-FS than other measures (d = 1.5).
Strober and Arnett (2010) [41] mBDI PwMS (DEP, NON-DEP) endorsed fatigue (p < .001), work
difficulty (p < .001), indecision (p < .01), irritability (p < .01),
loss of libido (p < .05), loss of interest (p < .01), crying
(p < .05), dissatisfaction (p < .05 and self-criticism (p < .05)
on the BDI
BDI and depression proneness rating scale,
r = .52, p < .01; BDI and CMDI, r = .76, p < .01
Amtmann et al. (2014) [33] PHQ-9; CESD-10; PROMIS-D-8 PHQ-9 with CESD-10 (.85); PROMIS-D-8 (.73). CESD-10
with PROMIS-D-8 (.80).
Fatigue scores correlations: PHQ 9 = .73;
CESD-10 = .71; PROMIS-D-8 = .55. Sleep
disturbance: PHQ-9 = .57; CESD-10 = .56;
PROMIS-D-8 = .39. Pain interference:
PHQ-9 = .60; CESD-10 = .55; PROMIS-D-8 = .47.
Pandya et al. (2005) [43]a CES-D MS with a major depressive disorder diagnosis had CES-D
score (36.5) than those who did not (26.0), Mann-Whitney = 12.1,
df = 1, p < .001
Patten et al. (2005) [44] CES-D CES-D scores did not correlate as highly with physical QoL,
as with mental QoL, Spearman's r = -.64. CES-D scores and the
physical, Spearman's r = .61, or the cognitive, Spearman's r = .66,
subscales of the fatigue impact scale.
CES-D scores correlated highly with mental
QoL, Spearman's r = -.80. CES-D scores and
the Fatigue Impact Scale social subscale,
Spearman's r = .74.
Verdier-Taillefer et al. (2001) [48] CES-D PwMS endorsed more depressed affect and fatigue items than
GP patients; MS and GP patients endorsed more depressive
symptoms than healthy workers (ps < .05)
Beeney and Arnett (2008) [35] CMDI Physical disability was correlated with vegetative subscale,
r(94) = .36, p < .05; mood, r(94) = .16, p = ns, or evaluative,
r(94) = .20, p = ns, subscales.
History of depression correlated with CMDI-
Mood, r(94) = .38, p < .001; CMDI-Evaluative,
r(94) = .31, p < .001; CMDI-Vegetative r(94) = .10,
p = ns. Depression proneness correlated with
mood, r(94) = .53, p < .001; evaluative, r(94) = .48,
p < .001, subscales; vegetative subscale,
r(94) = .15, p = ns.
Chang et al. (2003) [37] CMDI
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Table 3 Hypotheses Testing Findings by Measure (Continued)
PwMS scored higher on all dimensions than controls
(CMDI-Mood t = 6.10, p < .001, CMDI-Evaluative t = 6.61,
p < .001, CMDI-Vegetative t = 8.04, p < .001).
Nyenhuis et al (1995) [40] MDI PwMS endorsed more vegetative symptoms than mood
and evaluative, than the depressed group, controlling for
total BDI score F(2,322) = 5.7, p < .01; PwMS endorsed less
mood items than the depressed group, t(161) = 2.5, p < .05,
with no difference in evaluative, t(163) = 0.34, p > .10, or
vegetative, t(163) = -0.58, p > .10 items.
BDI (30.5 %) estimated depression significantly
greater than MDI-mood (17.7 %), p < .05; MDI-
Vegetative (34.6 %) estimated significantly
higher prevalence than MDI-Evaluative (22.2 %),
p < .05, and MDI-Mood, p < .01; MDI-Mood
estimated lower prevalence than MDI-Total
(26.6 %), p < .05.
Solari et al. (2003) [49] CMDI Significant differences in all subscale scores, p < .001. Adjusted
odds ratios for MS vs. healthy controls for depression was
2.72 (95%CI 1.14–6.50, p = .02) total scale; 2.79 (95 %CI 1.19–6.54,
p = .02); mood scale, 2.00 (95%CI 0.88–4.56, p = .10); evaluative
scale; 6.49 (95%CI 1.92–21.93, p = .001) vegetative scale.
Nicholl et al. (2001) [31] HADS-D HADS-D correlated with both the GHQ-12
(r = .49, p < .01), and the GHQ-28 (r = .48).
Kappa between HADS-D and BDI
0.12, p = .22.
Note: studies that are not included in the table either did not assess construct validity or did not report it. aPaper talks about Mann-Whitney chi square – test does not exist. QoL = Quality of Life; GHQ = General
Health Questionnaire
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Table 4 Criterion Validity Findings by Measure
Authors (Date) Measure Criterion Measure Correlation Sensitivity Specificity ROC Curve Analysis PPV NPV
Benedict et al (2003) [36] BDI-FS BDI, CES-D,
neuropsychiatric
inventory (NPI)
BDI r = .85, p < .001;
CES-D r = .86, p < .001;
NPI subscales range
r = .32-.50, ps < .05
Sullivan et al. (1995) [47] BDI Structured clinical
interview (DSM)
88 % (≥9), 71 % (≥13) 46 % (≥9),
79 % (≥13)
54 % (≥9), 70 %
(≥13)
84 % (≥9),
79 % (≥13)
Honarmand and
Feinstein (2009) [42]
HADS-D
(≥8)
SCID-I (DSM) 90 %, (95%CI 73–98)*
86.7 % (95%CI 68–96)*
fatigue item excluded
(≥6)
87.3 %,
(95%CI 81–92)*
86.7 %
(95%CI 80–92)*
fatigue item
excluded (≥6)
AUC = 0.94, 0.93 fatigue
item excluded (≥6)
90.6 %, 90.6 %
fatigue item
excluded (≥6)
Nicholl et al. (2001) [31] HADS-D BDI (Predictive) r = .58, p < .01 25 % - When using cut-
off of 5/6 (identified by
ROC curve), 75 %
86 % - When using
cut-off of 5/6
(identified by ROC
curve), 69 %
Identified the optimum
cut-off of 5/6 when
compared to the BDI.
Avasarala et al. (2003) [34] YSQ BDI (Cut-off of ≥13) 65.3 % (95%CI 50–78) 87.3 %
(95%CI 77–94)
78.0 %
(95%CI 62–89)
78.5 %
(95%CI 68–87)
Mohr et al. (2007) [38] Two-item
measure
SCID (DSM) Both questions: 51 %
(95%CI 38–63), either:
99 % (95%CI 91–100),
1 only: 75 % (95%CI
62–84), 2 only: 75 %
(95%CI 62–84)
Both: 98 %
(95%CI 94–99),
either: 87 %
(95%CI 81–91),
1 only: 94 %
(95%CI 89–97),
2 only: 94 %
(95%CI 89–97)
Both: 90 %
(95%CI 74–97),
either: 72 %
(95%CI 61–80),
1 only: 73 %
(95%CI 61–83),
2 only: 81 %
(95%CI 68–89)
Both: 85 %
(95%CI 80–89),
either: 99 %
(95%CI 96–100),
1 only: 91 %
(95%CI 86–95),
2 only: 91 %
(95%CI 86–95)
Pandya et al. (2005) [43] CES-D DSM-IV psychiatric
interview
59.6 % (95%CI
45.0–74.1) for major
depression; 74.5 %
(95%CI 61.5–87.4)
for any depressive
disorder.
Solari et al. (2003) [49] CMDI Previously diagnosed
according to DSM-IV
Total scale: 96.8 %;
mood: 96.9 %;
evaluative and
vegetative: 75.0 %
Vahter et al (2007) [50] One-item
measure
BDI (>10 cut-off) and
structured clinical
interview
81%a 89%a 93.5%a
Note: Studies that are not included in the table either did not assess criterion or did not report it.aExtracted from Manoj and Sivan (2007) [52] *Calculated by EL. SCID = Structured Clinical Interview for DSM Disorders;
ROC = Receiver operating characteristic
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Table 5 Methodological Quality of Each Article per Measurement Property and Instrument According to COSMIN Checklist
PAPERS Measure Internal
Consistency
Reliability Measurement
Error
Content Validity
(Face Validity Incl.)
Structural
Validity
Hypotheses
testing
Cross Cultural
Validity
Criterion
Validity
Responsiveness
Mohr et al. (1997) [70] BDI - - - Excellent - Fair - - -
Moran & Mohr (2005) [39] BDI - - Fair Excellent - Fair - - Fair
Sullivan et al. (1995) [47] BDI - - - Fair - Fair - Fair -
Aikens et al. (1999) [24] BDI-II Fair - - Excellent - Fair - - -
Benedict et al. (2003) [36] BDI-FS - - - Fair - Fair - Fair -
Strober & Arnett (2010) [41] mBDI - - - Excellent - Fair - - -
Pandya et al. (2005) [43] CES-D - - - - - Fair - Poord -
Patten et al. (2005) [44] CES-D - - - Excellent - Fair - - -
Patten et al. (2010) [45] CES-D - Fair Fair - - Good - - Fair
Verdier-Taillefer et al. (2001) [48] CES-D Good - - Excellent Good Good - - -
Amtmann et al. (2014) [33] CESD-10; PHQ-9;
PROMIS-D-8
Poora - - Fair Fair Fair - - -
Sjonnesen et al. (2012) [46] PHQ-9 Poorb - - Fair - Fair - - -
Beeney & Arnett (2008) [35] CMDI - - - Excellent - Fair - - Fair
Chang et al. (2003) [37] CMDI Fair - - Excellent Fair Fair - - -
Nyenhuis et al. (1995) [40] MDI - - - Fair - Fair - - -
Solari et al. (2003) [49] CMDI Fair Fair - Excellent - Fair Poorc - -
Honarmand & Feinstein (2009) [42] HADS - - - - - Fair - Fair -
Nicholl et al. (2001) [31] HADS - - - - - Good - Good -
Avasarala et al. (2003) [34] YSQ - - - - - Fair - Fair -
Mohr et al. (2007) [38] Two-item measure - - - Excellent - Fair - Fair -
Vahter et al (2007) [50] One-item measure - - - - - Fair - Fair -
Notes: a This paper was rated poor due to not calculating internal consistency for each subscale separately. b This paper was evaluated poor for not assessing the unidimensionality of the measure, although we
understand that might not have been the purpose of the study. c Multiple group Confirmatory Factor Analysis or Differential Item Function not performed/assessed. d No correlations or AUC calculated
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Hind et al. BMC Psychiatry  (2016) 16:278 Page 11 of 18neuropsychiatric inventory and strong correlations with
the BDI and CES-D [36]. The BDI-FS was strongly cor-
related (criterion validity) with the BDI-II (r = 0.85) and
CES-D (r = 0.86 [36]).
CES-D
For the reliability of the CES-D (n = 3), internal
consistency was excellent (α = 0.90 [48]), but inter-item
correlations were poor to acceptable (0.33–0.67 [33])
and test-retest reliability ranged from moderate (r =
0.65) to strong (r = 0.73) over different time intervals
[45]. In studies of content validity (n = 3 [33, 44, 48]),
there was strong agreement between the results of tests
with and without fatigue and cognition questions (r =
0.98–1.00; k = 0.90–0.96 [44]) suggesting that the instru-
ments were not contaminated by the presence of som-
atic symptoms common to MS and depression. The
issue of contamination is addressed fully in the Discus-
sion section. An investigation of face validity found that
CES-D captured a broad range of depression (including
mildly, moderate and severely depressed); however there
were conflicting results on the measure's structure for
the MS population [33, 44, 48]. For structural validity (n
= 2 [33, 48]) the fit indices for a one-factor CFA were ac-
ceptable, with CFI of ≥0.95, TLI <0.95 and a RMSEA
which did not meet the recommended level [33]. In an
exploratory factor analysis (EFA), four factors (depressed
affect, positive affect, somatic complaints and interper-
sonal relationships) explained more than 50 % of the
variance in test scores between MS and non-MS popula-
tions indicating good structural validity [48]. Studies
tested hypotheses related to the utility or predictive
value [43, 44], longitudinal utility [45], and the general
reliability and validity of the scale [48]. Using the DSM-
diagnosed MDD as a gold standard (criterion validity),
the PPV of the CES-D was 59.6 % [43]; the CES-D was
strongly correlated with the PHQ-9 (r = 0.85 [33]). For
responsiveness, insufficient data were available to calcu-
late the SEM [45].
CMDI
For the reliability of the CMDI (n = 2 [37, 49]), no over-
all value was available for internal consistency, but in-
ternal consistency of the subscales was generally
acceptable to excellent (α = 0.64–0.95 [37, 49]), the low
value being for sleep disturbance [37]. Researchers ob-
served intra-class correlations of 0.71 to 0.79 over two
weeks for test-retest reliability [37]; inter-item correla-
tions were moderate-to-strong for mood (0.58 to 0.80)
and evaluative (0.37 to 0.70) but moderate for vegetative
(0.32 to 0.57) subscales [49]. In studies of content valid-
ity (n = 4 [35, 37, 40, 49]), the vegetative subscale was
shown to be misfitting (unweighted item fit mean square
<0.7 or >1.3 [51]) with the MS participants more likelyto endorse the fatigue and feeling useless items than
controls [37]; investigation of face validity found that the
CMDI had a 'consistent overlap' with the MS symptoms
[35, 40, 49]. Studies tested hypotheses related to somatic
symptoms common to MS and depression (n = 2 [35,
40]), the general reliability and validity of the instrument
in people with MS (n = 1 [37]) and cross-cultural valid-
ation of the instrument (n = 1 [49]). Overall, the papers
consistently found that there should be a distinction be-
tween depression and MS symptoms and that the CMDI
provided a good measure for that. Regarding structural
validity (n = 1 [37]) a five-factor CFA found an excellent
fit between the proposed model and data, with CFI of
0.93, the normed fit index (NFI) of 0.90, the non-
normed fit index (NNFI) of 0.92. For responsiveness
there was insufficient data available in any study to cal-
culate the SEM [35]. There were no studies which
assessed criterion validity.
HADS
For the HADS, studies tested hypotheses related to the
general utility of the measure [31, 42] and found it to be
a useful screening instrument with high criterion-related
validity for depression. Using the DSM-diagnosed MDD
as a gold standard (criterion validity), the sensitivity and
specificity of the HADS were 90 and 87.3 % for the
whole scale or, 86.7 % for both when fatigue items were
excluded [42]. Using the BDI as a gold standard, the
HADS had a sensitivity and specificity of 75 and 69 %
respectively, and the two were moderately correlated (r
= 0.58 [31]). No study evaluated the reliability, the con-
tent validity, the structural validity or cross cultural val-
idity of the HADS.
PHQ-9
Regarding the reliability of the PHQ-9 (n = 2), internal
consistency was good (α = 0.82 [46]) with inter-item cor-
relations of 0.35–0.67 (moderate to acceptable [33]);
item-total correlations were good for anhedonia (0.71),
acceptable for depressed mood (0.65), and moderate for
fatigue (0.57) and concentration (0.55) subscales [46].
Fatigue items made the highest contribution to the total
score in all participants, with no significant differences
between MS and control participants (content validity
[46]). For structural validity (n = 1 [33]) the fit indices
for a one-factor CFA were acceptable, with a CFI of
>0.95, TLI <0.95 and the RMSEA did not meet the rec-
ommended level (>0.05). Studies tested hypotheses (n =
2) related to somatic symptoms [46] and the compara-
tive psychometric properties of different scales [33]. One
study tested hypotheses related to the convergent valid-
ity of PHQ-9, the CESD-10 and PROMIS-D-8 [33]. No
study evaluated the criterion validity or cross cultural
validity of the PHQ-9.
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validity of the YSQ. Using the BDI as a gold standard,
the sensitivity and specificity were 65.3 (95 CI 50–78)%
and 87.3 (95 % CI 77–94)% respectively [34]. No study
evaluated the reliability, content validity, structural valid-
ity, cross cultural validity or responsiveness
Discussion
Principal Findings
In this section, we summarise the evidence for dimensions
of validity across different instruments, referring in
brackets to the number of participants and the COSMIN-
rated quality of each study. The criterion validity of instru-
ments, using DSM-diagnosed MDD as a gold standard,
can be ranked in order of decreasing sensitivity and speci-
ficity, where reported, as follows. For sensitivity: (1) HADS
(n = 140; Fair) 90 %; (2) the one-item measure (n = 134;
Fair [50, 52]) 81 %; (3) BDI (n = 46; Fair [47]) 71 %; (4) the
two-item measure (n = 260; Fair [38]) 51 %. For specificity:
(1) the two-item measure (n = 260; Fair [38]) 98 %; (2) the
one-item measure (n = 134; Fair [50, 52]) 89 %; (3) HADS
(n = 140; Fair) 87 %; (4) BDI (n = 46; Fair [47]) 79 %. The
structural validity of instruments, using a variety of methods
can be ranked as follows. For CFA: (1) CMDI (n = 433;
Fair [37]) excellent; (2=) CESD (n = 455; Fair [33]) ac-
ceptable; (2=) PHQ-9 (n = 455; Fair [33]) acceptable.
There was little to distinguish the three measures
(CES-D, PHQ-9 and CMDI) in terms of their CFI scores
or, for the CES-D and PHQ-9, their TLI or RMSEA
scores (with the latter not meeting the recommended
level in either case). The method of assessing content
validity across studies varied widely, prohibiting any
ranking of studies. In brief, the CES-D (three studies
rated fair [33] or excellent [44, 48]) found no issue with
the inclusion of somatic symptoms, whereas the BDI (6
studies rated as fair [36, 47] or excellent [7, 24, 39, 41]),
and CMDI (3 studies rated as excellent [35, 37, 49])
identified some issues with the inclusion of somatic
symptoms in at least one study [24].
The most sustained debate on content validity sur-
rounded the BDI. While Mohr et al. (1997) [7], found that
‘fatigue’, ‘work difficulty’ and ‘concerns about health’ items
were MS-confounded (disproportionately endorsed within
PwMS) on the BDI, this was not confirmed by Aikens
et al. [24] (using the BDI-II), or Moran and Mohr [39],
who concluded all items were suitable for inclusion. Those
studies which presented an overall score for internal
consistency (reliability) can be ranked as follows: (1) CES-
D (n = 857; Good [48]) α = 0.90; (2) BDI-II (n = 105; Fair
[24]) α = 0.86; (3) PHQ-9 (n = 173; poor [46]) α = 0.82.
Strengths and limitations
The current review both updates and overcomes a num-
ber of limitations of the earlier review by Minden andcolleagues. First, our search strategy was considerably
more sensitive, identifying 15 eligible studies which had
been published at the time of the searches (August
2011) for the Minden article. Although our search strat-
egy is limited in its use of bibliographic databases, we
believe the associated risk of bias is low. When resources
are constrained, the use of Medline and PsycINFO,
along with checking reference lists, is justifiable in some
topic areas [53]. In mental health research, each data-
base performs well in the retrieval of mental health lit-
erature [54], and their use in combination is
recommended [55]. On the other hand, CINAHL rarely
retrieves unique references for most topic areas [56].
The exclusion of non-English language studies can have
more impact on the comprehensiveness of a review, al-
though there is no evidence that it causes systematic bias
[57]. Empirical evidence of bias stemming from the
omission of grey literature is available for systematic re-
views of therapeutic interventions [58], but not from re-
views of validation studies. The impact of this omission
on our review and the one by Minden and colleagues is
unknown, but future reviews might supplement searches
of bibliographic databases with grey literature databases
such as PsycEXTRA and the ProQuest Dissertations &
Theses Database, in addition to Google searches.
Systematic reviews which critically appraise and com-
pare the measurement properties of different instru-
ments can provide a sound basis for the selection of
instruments [59]. Unlike the Minden team, we took a
formal approach to the assessment of study quality using
the COSMIN checklist [23]. While some will find this
helpful, the rating of validation studies can be argued to
be subjective, especially on issues such as face validity.
We were unable to undertake statistical synthesis due to
the absence of confidence intervals associated with sum-
mary statistics in most reports. Our findings are also af-
fected by outcome reporting bias, especially in studies
evaluating reliability and criterion validity; for instance,
of 10 studies evaluating criterion validity seven pre-
sented sensitivity and specificity, eight presented PPV
and four presented NPV. Outcome reporting bias may
present a similar threat to the credibility of overviews of
validation studies as documented in systematic reviews
of therapeutic interventions [60, 61], and psychometri-
cians should consider following the Core Outcome Mea-
sures in Effectiveness Trials (COMET) initiative in the
development of core outcome sets for the COSMIN
domains [62].
Key messages for people with MS, therapists,
policy-makers
Item inclusion & symptom overlap
Concerns over item inclusion, given the overlap be-
tween MS and somatic depressive symptoms, were
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view, with self-report measures providing no oppor-
tunity to probe whether depressive symptoms are
influenced by disease severity [63]. Despite such
symptom overlap, the exclusion of items on this basis
is questionable [64]. A suggested alternative is the
use of different instruments, such as the BDI-FS,
which is less reliant on the somatic symptoms that
can confound assessment [36], or the BDI-II [65],
which removes a number of items that might be MS
related. Similarly, a different interpretation or ana-
lysis of standard BDI scores, such as the ‘trunk and
branch’ model proposed by Strober and Arnett, sep-
arating out those symptoms common to MS, may
help to overcome such issues of overlap [41]. An al-
ternate approach would be to adopt more generic
measures that assess extent to which physical and
mental health problems impact on a person’s quality
of life [66]. In this context, a lack of functioning or
activity impairment is important to the extent to
which it impacts on quality of life, rather than the
severity of their symptoms or condition. This might
involve the use of generic measure of health related
quality of life, such SF-36, or measures that better
reflect the impact of mental health problems identi-
fied in the literature [67].
Usefulness of measures
The one- or two-item measures [38, 50] may be prefera-
ble for use in people with MS (PwMS) as they are quick
and easy to administer, potentially overcoming any diffi-
culties arising from cognitive impairment [34]. Further-
more, they do not contain items relating to somatic
symptoms and so may overcome the overlap issues iden-
tified above. However, they only offer an indication of
the presence of depression and not its severity, which
may be useful to clinicians in identifying cases but not
to researchers in assessing treatment responsiveness, for
example.
Assessment criterion
Researchers and clinicians should consider the util-
ity of the measures discussed in relation to their
ability to identify probable cases of depression. As
such, when using self-report scales as a case finder,
it is important to identify the optimum cut-off value
[47]. This is difficult as studies often use different
cut-off values to signify a case (somebody who,
whilst not diagnosed, could benefit from talking
therapy) and sub-standard criterion against which to
assess the measure (e.g. the BDI rather than struc-
tured clinical interview). A robust criterion gives
greater confidence around the recommendation of
such cut-off values. This review suggests that themodification of the BDI, accounting for MS symp-
toms, may be an effective way to assess depression in
this patient group [63], though further independent
research is warranted.Need for further research
High quality validation studies are currently unavailable
and are needed on the following topics: the reliability of
the two-item measure, HADS, YSQ, the one-item meas-
ure; the structural validity of the BDI, two-item measure,
HADS, YSQ, the one-item measure; the cross-cultural
validity of the BDI (and its short-form variants), CES-D,
PHQ-9, CESD-10, PROMIS-D-8, two-item measure,
HADS, YSQ, the one-item measure; the responsiveness
of the two-item measure, HADS, YSQ, the one-item
measure review.
Further evidence is needed for most measures in asses-
sing their utility in this patient group, along with the ap-
propriateness of some of the items they use. Whilst item
exclusion may not be appropriate, altered scoring or inter-
pretation may be necessary. More investigation of existing
measures should seek to compare them against struc-
tured clinical interview, a gold standard measure,
given the questions raised regarding the validity of
the BDI [47]. Given the prevalence of BDI-based mea-
sures, further research should seek to validate the
BDI-II, mBDI and BDI-FS in people with MS. Use of
measures besides the BDI should be considered, such
as the HADS and PHQ-9, given their apparent ro-
bustness to confounding from MS symptoms. Asses-
sing the accepability of instruments to PwMS using
qualitative methods, such as Think Aloud method-
ology, is an essential complement to quantitative
evaluation [68, 69].Conclusions
All instruments identified in this review need further
work on validation and reliability for use in people with
MS. On the basis of the available evidence regarding
these measures, researchers and practitioners are faced
with trade-offs depending on their priorities. In addition,
researchers conducting further studies need to pay spe-
cial attention to the contamination of the depression in-
ventory scores overlapping with the MS symptoms.
However, it may be that a strategic re-evaluation is re-
quired in the approach to measuring depression in
people with MS. Rather than researchers pursing a
piecemeal approach to specific psychometric properties
of a range of outcome measures, an alternative might be
to move towards constructing and adopting Quality of
Life measures that emphasise the fulfilment of a person’s
needs rather than prioritising the severity of specific
symptoms.
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Authors (Date) Reason for Exclusion
Quaranta et al. (2012) [1] Measure was not self-report
Knox (2010) [2] Review/narrative
Manoj & Sivan (2007) [3]
Nocentini (2006) [4]
Doward et al. (2009) [5] Doesn’t assess depression
Fishman et al. (2004) [6]
Groom et al. (2003) [7]
McGuigan & Hutchinson (2004) [8]
Mueller & Girace (1988) [9]
O’Brien et al. (2007) [10]
Schwartz et al. (2011) [11]
Cook et al. (2012) [12] Doesn't assess validation of depression measure in MS
Gold et al. (2003) [13]
Horton et al. (2010) [14]
Provinciali et al. (1999) [15]
Alajbegovic et al. (2009) [16] Not a validation study
Good et al. (1992) [17]
Leon et al. (2001) [18] Sample not solely PwMS
Lykouras et al. (1998) [19]
Table 7 Study Characteristics
Authors (Date), Country Samples Baseline Characteristics MS Diagnosis
(years)
Disability Status Recruitment Method Measures Validity/ Reliability
Tested
Aikens et al. (1999) [20],
USA
MS=105,
Depressed=34,
Healthy=80,
Diabetes=71,
Chronic pain=80
MS: Mage=41.9(SD= 9.0), 63%
female; Depressed: Mage=39.3
(SD=14.6), 65% female; Healthy
controls: M age Mage=34.4
(SD=8.3), 50% female; Diabetes:
Mage=55.9 (SD=16.7), 56% female;
Chronic pain: Mage=45.0
(SD=13.9), 56% female
M = 11 years Expanded Disability Status
Scale = 0.0 - 7.5 (Median = 3.8)
Moderate Disability
University Hospital BDI-II Construct validity;
content validity;
internal reliability
(cronbach's alpha)
Amtmann et al. (2014)
[21], USA
MS = 455 Mage=52.9 (SD=10.8); 83%
female (N=377) and 17%
male (N=78);
M = 14.5
(SD = 10)
Moderate level University Hospital/
National Multiple
Sclerosis Society
charter
CESD–10,
PHQ-9
PROMIS-D-8
Evaluation of
dimensionality; inter-
item correlation;
discriminant/
convergent validity
Avasarala et al. (2003)
[22], USA
MS=120 Ages: 20–29 N=6, 30–39 N=25,
40–49 N=53, 50–59 N=32, 60–69
N=4; 71% female
NA NA University Hospital YSQ Criterion validity
Beeney and Arnett
(2008) [23], USA
3 year follow-up
MS=52; cross-
sectional analysis,
MS=96.
N=52: Mage=46.57 (SD=7.61);
N=96: Mage=47.41 (SD=8.98).
M (T1) =14.04
(SD = 9.37); M
(T2) = 16.87
(SD = 9.24)
EDSS (T1) =4.55 (SD = 1.44)
EDSS (T2) = 4.71 (SD = 1.61)
University Hospital/
National Multiple
Sclerosis Society
charter
CMDI Construct validity
Benedict et al. (2003)
[24], USA
MS=54 Mage=42.8 (SD=9.7), 79% female NA EDSS median = 2.5
(R = 0.0 - 7.0)
University Hospital BDI-FS Criterion and
construct validity
Chang et al. (2003)
[25], USA
MS=433; plus
'standardisation
sample' n=420
MS: Mage=45.0 (SD=10.0), 69.4%
female; Standardisation sample
described in Nyenhuis et al.
(1998) [26]: Mage=43.1
NA NA University Hospital CMDI Content validity,
internal reliability,
construct validity
Honarmand and
Feinstein (2009)
[27], Canada
Study 1: MS=140;
Study 2: MS=40,
MD=21, Matched
controls (no MD) = 19
Mage=44.6 (SD=10.3), 75% female M = 8.8
(SD = 6.8)
EDSS = 4.0 (SD = 2.34) Hospital HADS Criterion validity
Mohr et al. (1997)
[28], USA
MS =184, DEP =72,
controls (college
students) = 555
MS: Mage=44.0, 68% female; DEP:
Mage=47.5, 51% female; Controls:
Mage=20.2, 55%
NA NA University Hospital BDI Face validity
Mohr et al. (2007)
[29], USA
MS = 260 Mage=51 (SD=10.5), 73% female M = 19
(SD = 10.5)
NA University Hospital Two-item
measure
Criterion validity,
construct validity
Moran and Mohr
(2005) [30], USA
MS (with
depression)=42
Mage=43.0 (SD=10.3), 69% female M = 6.6
(SD = 6.1)
NA University Hospital/
referrals/ National
Multiple Sclerosis
Society Charter
BDI Construct validity
Nicholl et al. (2001)
[31], UK
MS=88 Mage=48.97 (SD=8.9), 75% female M = 11.8
(SD = 7.5)
NA Hospital/Rehabilitation
ward
HADS Criterion validity,
construct validity
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Table 7 Study Characteristics (Continued)
Nyenhuis et al.
(1995) [32], USA
MS=84, DEP=101,
controls (MS
matched)=87
MS: Mage=49.3 (SD=11.1), 75%
female; DEP: Mage=50.5 (SD=10.7),
65% female; Controls: Mage=49.6
(SD=11.6), 75% female
NA EDSS = 4.74 (SD = 3.6) Community based BDI, MDI Construct validity
Pandya et al. (2005)
[33], Canada
MS=47 Mage=39.3 (range 18–56), 72.3%
female
NA EDSS = 3.0 University hospital/
referrals to Psychiatric
care
CES-D Criterion validity,
construct validity
Patten et al. (2005)
[34], Canada
MS=567 Mage=48 (Range 19–76), 75.7%
female
NA NA University Hospital CES-D Construct validity
Patten et al. (2010)
[35], Canada
year 0 N=1670 year 1;
N=1336 year 2;
N=648, year 3 N=186
15.9% aged 18–34, 29.5% aged
35–44, 33.6% aged 45–54, 21.0%
aged 55+; 77.1% female
NA EDSS (mode) = 4 (R = 4–8) University Hospital CES-D Test-retest reliability
Sjonnesen et al.
(2012) [36], Canada
MS=173, Controls
(general
population)=3304
MS: Mage=52.9 (95%CI 51.2–54.6),
74.6% female; Controls: Mage=44.4
(95%CI 44.0–44.8), 67.7% female
M = 14.4
(95%CI = 13–
15.8)
27.1% (46/170) unable to work Patient Registry/
Hospital
PHQ-9 Content validity,
construct validity,
internal reliability
Solari et al. (2003)
[37], Italy
MS=213, Healthy
controls (matched
to MS)=213, DEP=32
MS: Mage=38 (SD=9.2), 66%
female; DEP: Mage=51.8
(SD=14.15), 78% female; Healthy
controls: Mage=38.3 (SD=9.4),
55.9% female.
M = 9.1
(SD = 6.9)
EDSS = 2.9 (SD = 1.6) University Hospital CMDI Internal reliability,
test-retest reliability,
content validity,
construct validity,
criterion validity
Strober and Arnett
(2010) [38], USA
MS-DEP=17, MS-NON-
DEP=67, healthy
controls=22
MS-DEP: Mage=45.24 (SD=8.39),
82% female; MS-NON: Mage=47.93
(SD=9.30), 84% female; Controls:
Mage=46.18 (SD=13.36), 82%
female.
M depressed
- 10.59
(SD = 6.42)
M MS-NON =
11.15
(SD = 8.66)
EDSS depressed = 5.18 (SD = 1.5)
EDSS MS- NON= 4.32 (SD = 1,54
National Multiple
Sclerosis Society
charter
mBDI Construct validity
Sullivan et al. (1995)
[39], Canada
MS=46 Mage=34.4, 78% female NA NA Hospital/ referrals BDI Criterion validity,
construct validity
Vahter et al. (2007)
[40], Estonia (from
Manoj and Sivan,
2007 [31])
MS=134 Mage=43.8 (SD=12.4), 73.9%
female
M = 9.9
(SD = 8.5)
EDSS = 5.8 (SD = 2.5) Hospital One-item
measure
Criterion validity
Verdier-Taillefer et al.
(2001) [41], France
MS=857, GP
patients=1598,
healthy workers=403
MS: Mage=47.0 (SD=7.2), 63.2%
female; GP patients: Mage=44.6
(SD=8.8), 59.1% female; Healthy
workers: Mage=42.9 (SD=6.3),
55.3% female
NA NA CES-D Content validity,
internal reliability,
construct validity
Note: MS Multiple Sclerosis, MD Major Depression, DEP Depressed, NA Not Available
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